In February 2016, Ambroxol was formally announced as one of CPT's Linked Clinical Trials (LCT) candidates to be tested in people with Parkinson's. Ambroxol performed exceptionally well in preclinical studies for Parkinson’s and is already approved to treat other conditions.  

By focusing on existing medications that have already passed the rigorous drug approval process and shown promise in preclinical laboratory studies for treating Parkinson’s, the LCT aims to significantly reduce the time and cost required to bring new therapies to people with Parkinson’s now.

Wishing all our supporters a very Happy Christmas and a Wonderful New Year!

................................................................................................

 

Find out more about CPT's Linked Clinical Trials